Publications by authors named "Marco Frigeni"

Claim this Profile
F
First-Tier Versus Last-Tier Trio Whole-Genome Sequencing for the Diagnosis of Pediatric-Onset Rare Diseases.
Camilla Lucca, Erica Rosina, Lidia Pezzani, Daniela Piazzolla, Luigina Spaccini, Marco Frigeni

Clin Genet· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.
Martin Hutchings, Koorosh Korfi, Pau Montesinos, Armando Santoro, Hsin-An Hou, Marco Frigeni

Blood Neoplasia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06.
Gianluca Cavallaro, Silvia Salmoiraghi, Roberta Cavagna, Chiara Pavoni, Clara Belotti, Marco Frigeni

Leuk Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.
Giovanni Marconi, Alfonso Piciocchi, Ernesta Audisio, Cristina Papayannidis, Marco Cerrano, Marco Frigeni

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.
Francesco Mannelli, Matteo Piccini, Marco Frigeni, Giacomo Gianfaldoni, Sara Bencini

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome.
Carmelo Gurnari, Elisa Galossi, Eleonora Lumia, Alfonso Piciocchi, Mariadomenica Divona, Marco Frigeni

Br J Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study.
Annalisa Condorelli, Marco Frigeni, Giulia Quaresmini, Silvia Salmoiraghi, Chiara Pavoni

Leuk Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Carmelo Gurnari, Maria Rosaria Pascale, Antonio Vitale, Elisa Diral, Alessandro Tomelleri, Marco Frigeni

Am J Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination-Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda.
Giuseppe Rossi, Erika Borlenghi, Patrizia Zappasodi, Federico Lussana, Massimo Bernardi, Marco Frigeni

Cancers (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Luca Lanino, Francesco Restuccia, Alessandra Perego, Marta Ubezio, Bruno Fattizzo, Marco Frigeni

Am J Hematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.
Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, Diego Ripamonti, Ivano Riva, Marco Frigeni

Leukemia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.
Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, Diego Ripamonti, Ivano Riva, Marco Frigeni

Leukemia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Diagnosis of Acute Myeloid Leukemia and Symptomatic COVID-19 Infection: a Case Report Successfully Treated with Azacitidine-Venetoclax Combination.
Daniela Taurino, Marco Frigeni, Anna Grassi, Gianluca Cavallaro, Silvia Salmoiraghi

Mediterr J Hematol Infect Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.
Irene Defrancesco, Marcella Visentini, Silvia Zibellini, Ylenia Aura Minafò, Sara Rattotti, Marco Frigeni

Am J Hematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.
Irene Defrancesco, Silvia Zibellini, Emanuela Boveri, Marco Frigeni, Virginia Valeria Ferretti

Hematol Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
Alessandro Rambaldi, Giuseppe Gritti, Maria Caterina Micò, Marco Frigeni, Gianmaria Borleri

Immunobiology· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
Michele Merli, Irene Defrancesco, Carlo Visco, Caroline Besson, Alice Di Rocco, Marco Frigeni

Leuk Lymphoma· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
Marco Frigeni, Caroline Besson, Carlo Visco, Helene Fontaine, Maria Goldaniga

Leukemia· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis.
Marine Lemaitre, Pauline Brice, Marco Frigeni, Olivier Hermine, Luca Arcaini

J Infect· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.
Stefano Luminari, Michele Merli, Sara Rattotti, Vittoria Tarantino, Luigi Marcheselli, Marco Frigeni

Blood· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Michele Merli, Marco Frigeni, Laurent Alric, Carlo Visco, Caroline Besson

Oncologist· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
Sara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi, Andrea Rossi, Stefano Fogazzi, Marco Frigeni

Hematol Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas.
Michele Merli, Marco Frigeni, Manuel Gotti, Paolo Grossi, Raffaele Bruno

Hepatology· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.
Manuel Gotti, Marta Nicola, Marco Lucioni, Valeria Fiaccadori, Virginia Ferretti, Marco Frigeni

Hematol Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
Luca Arcaini, Caroline Besson, Marco Frigeni, Hélène Fontaine, Maria Goldaniga

Blood· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis